Skip to main content

Table 1 Characteristics of the 33 patients

From: Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease

Variables

Total (n = 33)

Age at onset of MAC, yrs ± SD

57 ± 12

Age (when found to be resistant), yrs ± SD

67 ± 9

Female, n (%)

31 (93.9)

Body mass index, kg/m2 ± SD

17.2 ± 5.0

Smoking history, n (%)

 

 Current/Former/Never

0 (0)/3 (9.1)/30 (90.9)

 Pack-years ≥20, n (%)

1 (3.0)

 Alcohol abuse, n (%)

1 (3.0)

Underlying respiratory disease, n (%)

 

 Old pulmonary tuberculosis

2 (6.1)

 Bronchiectasis

2 (6.1)

 Interstitial pneumonia

1 (3.0)

Underlying systematic disease, n (%)

 

 Old cerebral infarction

1 (3.0)

 Diabetes mellitus

1 (3.0)

Radiographic features, n (%)

 

 NB/FC

8 (24.2)/25 (75.8)

 Total lesion extenta 1/2/3, n (%)

2 (6.1)/24 (72.7)/7 (21.2)

 Cavity at the beginning of treatment, n (%)

25 (75.8)

Laboratory

 

 White blood cell, /μl ± SD

5590 ± 1437

 Neutrophil, /μl ± SD

3915 ± 1291

 Hemoglobin, g/dl ± SD

12.4 ± 1.3

 Serum albumin, g/dl ± SD

3.8 ± 0.6

 CRP, mg/dl ± SD

1.9 ± 2.9

 AST, mg/dl ± SD

23 ± 7

 ALT, mg/dl ± SD

15.9 ± 8.4

 Cre, mg/dl ± SD

0.5 ± 0.14

Chronic infection with P. aeruginosa

3 (9.1)

With treatment for pulmonary aspergillosis, n (%)

4 (12.1)

Steroid use, n (%)

0 (0)

Past MAC treatment

 

 CAM monotherapy, n (%)

6 (18.2)

 Two-drug regimen including CAM, n (%)

4 (12.1)

 MAC treatment more than 5 years, n (%)

20 (60.6)

  1. Data are presented as no. (%) or mean ± SD
  2. MAC Mycobacterium avium complex, NB nodular/bronchiectatic disease, FC fibrocavitary disease, CRP C-reactive protein, AST aspartate transaminase, ALT alanine transaminase, Cre creatinine, CAM clarithromycin
  3. a1, within one third of unilateral lung field; 2, within unilateral lung field; 3, over unilateral lung field